Research view
Switch to patient viewFatty liver disease (MASLD/MASH): trials that stopped early
Trials on Fatty liver disease (MASLD/MASH) that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.
Stopped early
30 stopped trials give a reason in the registry, latest registry update first.
Terminated
Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis
Reason given in the registry “Study has been terminated due to poor recruitment and early evidence of futility”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Sept 2026.
- Ended
- Jun 2026
- Run by
- University of Minnesota
- Registry record
- NCT03587831
Suspended
NAFLD in Adolescents and Young Adults With PCOS
Reason given in the registry “Lack of funding”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Sept 2026.
- Run by
- Columbia University
- Registry record
- NCT02506946
Terminated
Non-alcoholic Steatohepatitis Registry Platform Study
Reason given in the registry “Following a reassessment of the company's pipeline priorities, the sponsor has elected to discontinue this project prior to its planned completion”
Quoted unchanged from ClinicalTrials.gov; record updated 29 Jul 2026.
- Ended
- Oct 2025
- Run by
- AstraZeneca
- Registry record
- NCT06123858
Withdrawn
GLP-1 RA on Liver OMICS in MASLD
Reason given in the registry “no grant approved”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Jul 2026.
- Ended
- Jul 2026
- Run by
- Medical College of Wisconsin
- Registry record
- NCT06982378
Withdrawn
Assessment of Fatty Liver With Thermo-acoustic Device
Reason given in the registry “The sponsor withdrew from the study”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Jul 2026.
- Ended
- Jul 2026
- Run by
- Medical College of Wisconsin
- Registry record
- NCT04302051
Terminated
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
Reason given in the registry “Based on FDA feedback, Stage 1 of NAVIGATE was analyzed as a stand-alone trial. Study was not prematurely terminated for safety reasons.”
Quoted unchanged from ClinicalTrials.gov; record updated 30 Jun 2026.
- Ended
- Apr 2025
- Phase
- Phase 2/3
- Run by
- Galectin Therapeutics Inc.
- Registry record
- NCT04365868
Terminated
Prevention of NAFLD in Hispanic Children
Reason given in the registry “Study was terminated due to a lack of funding. Data collection was completed for 12-month outcomes; however, funding limitations prevented follow-up for longer timeframes, and some outcomes were not fully collected.”
Quoted unchanged from ClinicalTrials.gov; record updated 2 Jun 2026.
- Ended
- Mar 2026
- Run by
- Emory University
- Registry record
- NCT05292352
Terminated
Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)
Reason given in the registry “Pilot cohort (n=10) yielded useful insights but data remains exploratory due to limited sample size. Study stopped due to strategic reprioritization.”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Apr 2026.
- Ended
- Mar 2026
- Phase
- Phase 2
- Run by
- Enyo Pharma
- Registry record
- NCT06939816
Terminated
A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)
Reason given in the registry “Participants were not dosed in Part B as per the protocol.”
Quoted unchanged from ClinicalTrials.gov; record updated 13 Apr 2026.
- Ended
- Feb 2025
- Phase
- Phase 1
- Run by
- Eli Lilly and Company
- Registry record
- NCT06007651
Withdrawn
FCI Effectiveness in NAFLD Stratification
Reason given in the registry “Funding period ended.”
Quoted unchanged from ClinicalTrials.gov; record updated 1 Apr 2026.
- Ended
- Mar 2026
- Run by
- NHS Grampian
- Registry record
- NCT05827432
Withdrawn
Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy
Reason given in the registry “The sponsor determined that enrollment would not meet their expectations and decided to withdraw the study.”
Quoted unchanged from ClinicalTrials.gov; record updated 23 Feb 2026.
- Ended
- Nov 2025
- Run by
- University of California, San Diego
- Registry record
- NCT07255781
Suspended
A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
Reason given in the registry “Interim analysis results from the open-label part of the study. The double blind portion of the study will be resumed once the study will continue.”
Quoted unchanged from ClinicalTrials.gov; record updated 11 Feb 2026.
- Phase
- Phase 3
- Run by
- Galmed Research and Development, Ltd.
- Registry record
- NCT04104321
Suspended
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
Reason given in the registry “Suspended for analysis and to consider further enrollment.”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Jan 2026.
- Run by
- University of Pittsburgh
- Registry record
- NCT04306939
Terminated
Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)
Reason given in the registry “Sponsor Decision”
Quoted unchanged from ClinicalTrials.gov; record updated 18 Dec 2025.
- Ended
- Oct 2024
- Phase
- Phase 2
- Run by
- Zydus Therapeutics Inc.
- Registry record
- NCT03617263
Terminated
A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4
Reason given in the registry “Study was terminated early by the sponsor due to a strategic shift and reprioritization of clinical programs within Takeda.”
Quoted unchanged from ClinicalTrials.gov; record updated 19 Aug 2025.
- Ended
- Dec 2024
- Phase
- Phase 1
- Run by
- Takeda
- Registry record
- NCT07052682
Withdrawn
Digital Therapeutic Lifestyle Intervention Program for Patients With MASLD
Reason given in the registry “Principal investigator left the institution and study was never funded”
Quoted unchanged from ClinicalTrials.gov; record updated 25 Jul 2025.
- Run by
- Milton S. Hershey Medical Center
- Registry record
- NCT06352177
Terminated
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.
Reason given in the registry “AstraZeneca have decided to not move forward with the development of the compound.”
Quoted unchanged from ClinicalTrials.gov; record updated 20 Jul 2025.
- Ended
- Mar 2024
- Phase
- Phase 1
- Run by
- AstraZeneca
- Registry record
- NCT05864391
Withdrawn
Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease
Reason given in the registry “Institutional and funding constrains”
Quoted unchanged from ClinicalTrials.gov; record updated 14 Jul 2025.
- Ended
- Dec 2024
- Phase
- Phase 1/2
- Run by
- Sadat City University
- Registry record
- NCT04761848
Withdrawn
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis
Reason given in the registry “Business decision”
Quoted unchanged from ClinicalTrials.gov; record updated 15 May 2025.
- Phase
- Phase 3
- Run by
- Sagimet Biosciences Inc.
- Registry record
- NCT06594523
Withdrawn
A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH
Reason given in the registry “Business decision”
Quoted unchanged from ClinicalTrials.gov; record updated 15 May 2025.
- Phase
- Phase 3
- Run by
- Sagimet Biosciences Inc.
- Registry record
- NCT06692283
Withdrawn
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH
Reason given in the registry “This study has been cancelled due to business reasons”
Quoted unchanged from ClinicalTrials.gov; record updated 27 Sept 2024.
- Ended
- Jan 2025
- Phase
- Phase 2
- Run by
- Gannex Pharma Co., Ltd.
- Registry record
- NCT05118360
Terminated
Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
Reason given in the registry “Trial terminated because of lack of efficacy in the short term acute phase.”
Quoted unchanged from ClinicalTrials.gov; record updated 4 Sept 2024.
- Ended
- Feb 2024
- Phase
- Phase 2
- Run by
- Bristol-Myers Squibb
- Registry record
- NCT04267393
Withdrawn
Dexamethasone/Pancreatic Clamp P&F
Reason given in the registry “Investigators' scientific priorities shifted.”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Jul 2024.
- Ended
- Mar 2026
- Phase
- Phase 1
- Run by
- Columbia University
- Registry record
- NCT06126354
Withdrawn
A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
Reason given in the registry “The study was withdrawn because BioMarin decided to end the overall development program. The study withdrawal was not due to any patient safety concerns.”
Quoted unchanged from ClinicalTrials.gov; record updated 11 Jun 2024.
- Ended
- Mar 2024
- Phase
- Phase 1
- Run by
- BioMarin Pharmaceutical
- Registry record
- NCT06138327
Terminated
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)
Reason given in the registry “Study ALN-HSD-001 was terminated due to business reasons and changes in the development strategy of the product. No safety issues were found.”
Quoted unchanged from ClinicalTrials.gov; record updated 17 May 2024.
- Ended
- Dec 2023
- Phase
- Phase 1
- Run by
- Alnylam Pharmaceuticals
- Registry record
- NCT04565717
Withdrawn
A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally in Subjects With Nonalcoholic Fatty Liver Disease
Reason given in the registry “lack of funds”
Quoted unchanged from ClinicalTrials.gov; record updated 14 May 2024.
- Ended
- Dec 2024
- Phase
- Phase 2
- Run by
- The University of Texas Health Science Center, Houston
- Registry record
- NCT04371653
Terminated
Systems Biology of Gastrointestinal and Related Diseases
Reason given in the registry “Lack of enrollment.”
Quoted unchanged from ClinicalTrials.gov; record updated 15 Dec 2023.
- Ended
- Nov 2023
- Run by
- Viome
- Registry record
- NCT05579444
Terminated
Utilization of MAsS in Patients Undergoing LT for HCC
Reason given in the registry “Discontinued by Amra Medical due to funding.”
Quoted unchanged from ClinicalTrials.gov; record updated 7 Dec 2023.
- Ended
- Nov 2023
- Run by
- Columbia University
- Registry record
- NCT05184283
Withdrawn
Effects of Mindfulness Based Stress Reduction Intervention in Patients With Non-alcoholic Fatty Liver Disease
Reason given in the registry “The study is being withdrawn due to difficulties enrolling participants and the loss of the study coordinator”
Quoted unchanged from ClinicalTrials.gov; record updated 8 Feb 2023.
- Ended
- Dec 2023
- Run by
- Virginia Commonwealth University
- Registry record
- NCT05130346
Suspended
A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity
Reason given in the registry “This study was terminated due to expired drug with possibility of re-starting in the future.”
Quoted unchanged from ClinicalTrials.gov; record updated 10 Feb 2021.
- Phase
- Phase 2
- Run by
- University of California, San Diego
- Registry record
- NCT00546455
Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.